Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your VWF activity assay might be giving you the wrong answer.
And that wrong answer changes everything downstream.
VWF:RCo has been the workhorse of VWD testing for decades.
But here’s what the data actually shows:
- VWF:RCo imprecision sits around 9%. GPIb-based assays? Around 3.2%.
- Ristocetin-sensitive polymorphisms can falsely lower the activity:Ag ratio. That’s not biology. That’s assay noise.
- In diverse populations, this creates a predictable disadvantage. The same patient, different ethnicity, different result. That’s an equity problem.
Why does this matter so much?
The VWF activity result sits at the centre of the subtype algorithm. I
f that number drifts, everything drifts with it:
- Type 1 patients get pushed into a Type 2 work-up
- Unnecessary multimers, RIPA, genetics referrals follow
- DDAVP decisions and perioperative plans change
- Borderline cases get missed entirely
VWF:GPIbM offers a way out.
No ristocetin dependence.
No polymorphism distortion.
92% Type 2 sensitivity. 85.1% Type 1 specificity. Same 0.70 activity:Ag ratio threshold. Same diagnostic logic.
The message is simple: modernise the assay, preserve the pathway.
Both BSH 2024 and ASH/ISTH 2021 guidelines point the same direction.
But this isn’t just a reagent swap.
It’s a quality programme.
- Validation
- Reporting language
- Clinical education
- Post-go-live review
All need to land together.
I built an interactive guide to walk laboratories through this transition step by step.
- Assay comparison
- Decision algorithms
- Implementation framework
- Rhe evidence behind each choice
All in one place.
Has your lab made this switch yet?
What held you back, or what pushed you forward?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Sep 17, 2026, 20:19Riten Kumar: Boston Children’s Hospital Ranked No. 1 in Seven Pediatric Specialties
-
Sep 17, 2026, 20:17Katrina Snow: Whole Blood or Component Therapy – Which Would You Choose?
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications